DDX53 and colon carcinoma: In syngeneic colon carcinoma, APMV-4 and rAPMV-4 virotherapies resulted in 100% elimination of CT26.WT tumors, outmatching the therapeutic effect of LS-L289A (40% CR; Fig. 6D and E).